QuarterHawk — Equity ResearchQuarterHawk — Equity Research

ADMA Biologics, Inc. (ADMA)

Healthcare

Actionable
Fundamental
4
Sentiment
3
Technical
4

Buy limit 13.05 on a pullback to the 13.04 higher-low / breakout-retest support with the uptrend intact (price above SMA20/50/200 and EMA9/21, ADX 32.48 rising, MACD 0.72 > signal 0.56 > 0); protective stop 12.41 below the 12.48-12.60 base (pullback ATR floor, 1.0x ATR), targets 14.33 / 15.29, R/R 2.00. The breakout alternative (buy-stop above the settled 13.52 high at 13.55) was rejected: R/R 1.19 with the 13.77 catalyst high overhead.

Analysis as of 2026-11-13· more than 2 trading days ago

Company overview

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing plasma-derived biologic therapies. Its products, including BIVIGAM and ASCENIV, target immune system disorders and infectious diseases. The company also manages plasma collection facilities and distributes its products through various channels.

Fundamental

good
Fundamental4
Solid fundamentals

ADMA Biologics shows strong profitability and cash generation, but faces growth deceleration and litigation risks.

Strongly profitable, cash-generative plasma-derived biologics manufacturer: 70% gross margin, 35% trailing net margin, net debt/EBITDA 0.31x, 22x interest coverage and an aggressive buyback, offset by decelerating revenue (+2.4% in the first nine months of 2026), heavy ASCENIV and distributor concentration, a newly filed securities class action and $191.6M of debt maturing in 2028. Shares trade near 16.8x trailing earnings and 11.9x EV/EBITDA against a $19.50 analyst consensus target.

Sentiment

fair
Sentiment3
Mixed sentiment

Recent earnings beat is priced in, with a legal overhang and indeterminate retail sentiment affecting outlook.

The dominant catalyst is the Q3 2026 print (2026-11-04, announced) — a genuine beat-and-raise with ASCENIV revenue +31% y/y, GAAP EPS $0.22 and a raised adjusted earnings outlook — which the tape rewarded with a ~28% after-hours jump to a 10-month high, and the 14-day media delta is determinately positive against the baseline (polarity ≈ −0.07 across 11 scored baseline items → +0.31 across 9 scored scoring-window items). The read is capped by a moderate red-flag screen — a court-docket-confirmed consolidated securities class action (Mazzarino v. ADMA Biologics, No. 26-cv-6918) alleging channel stuffing and an undisclosed related-party distributor deal — so the moderate red-flag cap applies, a nine-day-old largely-digested catalyst with no forward event inside 30 days keeps the setup below the top band, and retail sentiment is indeterminate (Reddit 403 on both queries).

Technical

good
Technical4
Confirmed uptrend

ADMA is in a short-term uptrend with price above key moving averages, supported by rising ADX and MACD indicators.

ADMA is in a confirmed short-term uptrend. The price of 13.24 is above its SMA20 (11.64), SMA50 (10.49), SMA200 (10.74), EMA9 (12.49) and EMA21 (11.75); MACD is 0.72 versus a signal of 0.56 with an expanding histogram of 0.16 since 2026-11-05; and ADX14 at 32.48 is rising. The 2026-11-05 catalyst-day reversal (+9.99% to 13.21 on 15.0M shares) has been followed by constructive consolidation that carved a higher low at 13.04 (2026-11-12) above 12.60 (2026-11-11), favoring a pullback-to-support entry at the retest of that higher low rather than a chase into the overhead 13.77 catalyst high. Overbought-ish short-term momentum (RSI 68.35, Williams %R -15.06) after a roughly 26% six-session run and a close just under daily VWAP (13.24 versus 13.2575) are the offsetting cautions, which is why the chart is scored 4 rather than 5. ATR14 is 0.64 (4.83% of price), which supports a 13.05 limit with a 12.41 stop (1.0x ATR below entry per the pullback floor) and ATR targets of 14.33 and 15.29 (R/R 2.00). A breakout stop above 13.55 was evaluated and rejected at R/R 1.19.

You’re looking at 2026-11-13 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.